Liver Cancer News and Research

RSS

Liver cancer is more common in older people. Over half of people newly diagnosed with liver cancer are age 65 and over. Liver cancer is more common in men than in women. Liver cancer rates are highest among Asians and Pacific Islanders, most likely because of higher prevalence of viral Hepatitis infection. Liver cancer rates are lower among whites than Blacks or Asians and Pacific Islanders. At this time, we do not know exactly what causes cancer of the liver. There are several different types of liver cancer. The most common type is associated with long-term excessive alcoholic beverage use, scarring of the liver (cirrhosis), and Hepatitis B virus or Hepatitis C virus infection. Long-term use of anabolic steroids can also increase the risk of getting liver cancer. Smoking is also believed to increase the risk of getting liver cancer.

Provectus reports on end-of-Phase 2 meeting with FDA on licensure of PV-10 for metastatic melanoma

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced today that it has held an end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) to seek consensus on clinical program scope and endpoints for licensure of PV-10 for metastatic melanoma. The meeting was held at the Agency's White Oak Campus in Silver Spring, MD.

29 Apr 2010

Study investigates efficacy of acellular dermal matrix for intestinal elongation

Acellular dermal matrix (ADM) is a dermal biomaterial in which all of the cellular elements have been removed. The biologic properties of ADM, including its ability to support tissue regeneration repopulation with fibroblasts, revascularization, new collagen deposition and eventual absorption and replacement with native tissue permit its use in tissue reconstruction.

29 Apr 2010

OSI Pharmaceuticals announces European Commission's approval of Tarceva for NSCLC

OSI Pharmaceuticals, Inc. announced today that its international partner for Tarceva® (erlotinib), Roche, received approval from the European Commission for Tarceva as a monotherapy maintenance treatment in patients with advanced non-small cell lung cancer (NSCLC) whose disease remains largely unchanged (stable disease) after platinum-based initial chemotherapy.

29 Apr 2010

Presence and type of cirrhosis complications are strong predictors of mortality: Study

A recent study by Danish researchers discovered patients with alcoholic cirrhosis had a high prevalence of complications at the time of the disease diagnosis.

29 Apr 2010

Investigators study Pioglitazone and Vitamin E for treatment of NASH

A daily dose of a specific form of vitamin E significantly improved the liver disease, nonalcoholic steatohepatitis, according to a study funded by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health. Results were published April 28 online in the New England Journal of Medicine.

29 Apr 2010

SBRT shows promise in treatment of lung, liver and spinal tumors: Clinical experts

Radiosurgical approaches to cancer treatment are showing promise in the treatment of lung, liver, and spinal tumors, according to four leading clinical experts who presented at a symposium in New York earlier this month.

28 Apr 2010

ChronSeal multi-center study in Sweden and Norway finalized

The multi-center study in Sweden and Norway with ChronSeal® is now finalized and the data are being analyzed in Sweden and by Kringle in Japan. ChronTech and Kringle have jointly decided that the results will be publicly available on May 27th. At follow-up of the ChronVac-C® -study where patients now have started treatment according to standard-of-care (interferon and ribavirin) all patients (100%) were virus free at treatment week 12 and 5/6 (83%) had less than 50 copies of virus/mL blood already at treatment week four.

28 Apr 2010

FDA grants NexMed clearance for HCC Phase 2 trial for PrevOnco

NexMed, Inc., a specialty CRO with a pipeline of products based on the NexACT® technology, today announced that the U.S. Food & Drug Administration (FDA) has cleared the Company to proceed with the proposed Phase 2 trial of PrevOnco™, its proprietary cancer treatment for patients with advanced, unresectable hepatocellular carcinoma (HCC), or liver cancer. The FDA granted PrevOnco™ orphan drug status in August 2008, and in March 2010, NexMed filed its Investigational New Drug (IND) application for the product candidate.

27 Apr 2010

Pfizer announces discontinuation of SUN 1170 Phase 3 study of Sutent in HCC

Pfizer Inc. announced today the discontinuation of the SUN 1170 Phase 3 open-label study of Sutent(r) (sunitinib malate) in advanced hepatocellular carcinoma, or liver cancer. Following a review by the independent Data Monitoring Committee, the study was discontinued based on a higher incidence of serious adverse events in the sunitinib arm compared to the sorafenib arm and the fact that sunitinib did not meet the criteria to demonstrate that it was either superior or non-inferior to sorafenib in the survival of patients with advanced hepatocellular cancer.

23 Apr 2010

New studies on cancer prevention presented at 101st AACR Annual Meeting 2010

Interest in cancer prevention is increasing as scientists continue to learn new information and confirm what was already suspected.

22 Apr 2010

COX-2 expression not an adequate independent prognostic factor: Research

Cyclooxygenase-2 represents a key modulatory molecule in inflammation and carcinogenesis. COX-2 is known to have multiple tumorigenic effects. Increased expression of COX-2 has been observed in a variety of tumors including pancreatic cancer.

22 Apr 2010

Study helps understand molecular mechanism underlying taurine's protection against hepatic fibrosis

Hepatic fibrosis (HF) occurs in most types of chronic liver diseases and approximately 25%-40% of HF cases may ultimately progress to hepatic cirrhosis. Hepatic stellate cells (HSCs) contribute significantly to the occurrence of HF and the activation of HSC is the key issue in the pathogenesis of HF. Taurine is a kind of important anti-injury substance in the body.

21 Apr 2010

Researchers demonstrate role of HSP-90 in portal hypertension

Neural vasoregulation represents a rapid and potent mode of altering vascular tone but has not been investigated thoroughly during portal hypertension. Heat shock protein-90 is well-known to act as a molecular chaperone optimizing endothelial and neural NO-synthase enzyme activity and thus, NO production.

21 Apr 2010

miRNAs may generate new insights on cancer and possible future treatments

Scientists are methodically unlocking the biological processes that lead to cancer, and recent discoveries with microRNAs (miRNAs) are revolutionizing their understanding and leading to clinical trials of potentially effective treatments.

21 Apr 2010

Diagnosis of gastric adenomyoma remains a challenging issue

Gastric adenomyoma (AM) is a rare, benign tumor, characteristically composed of glands and cysts, lined by columnar, flattened epithelia and a prominent smooth muscle stroma. Patients with gastric AM may be asymptomatic, or present as nonspecific gastrointestinal symptoms.

21 Apr 2010

New research indicates patients may develop anemia after gastric bypass surgery

Morbid obesity is one of the most common causes of morbidity and mortality in Western countries. Roux-en-Y gastric bypass (RYGB) has become a common procedure for achieving short- and long-term weight loss. It has gained great popularity among surgeons and patients in recent years. Long

21 Apr 2010

Celsion's ThermoDox Phase I trial data presented at 9th IHPBA World Congress

Celsion Corporation today announced that Dr. Thanjavur S. Ravikumar, from the Geisinger Health System and a principal investigator of the Phase I ThermoDox® dose escalation trial, gave an oral presentation at the Liver Tumors Panel session of the 9th World Congress of the International Hepato-Pancreato-Biliary Association (IHPBA) in Buenos Aires, Argentina.

21 Apr 2010

AngioDynamics commences treatment in NanoKnife IRE System pilot study for HCC

AngioDynamics today announced the first patient treatment and growing enrollment in a pilot study of the use of the Company's NanoKnife® Irreversible Electroporation (IRE) System in the treatment of early stage hepatocellular carcinoma (HCC), or primary liver cancer. This clinical trial is being conducted under the supervision of Professor Jordi Bruix of the Barcelona Clinic Liver Cancer Group of the University of Barcelona and Professor Riccardo Lencioni of the University of Pisa School of Medicine.

20 Apr 2010

Temporary occlusion of portal vein may help avoid I/R-related complications in liver surgery

Liver surgery has become a safe procedure in the past years and is mainly done because of malignant tumors. A common strategy to reduce blood loss during surgery is to temporarily shut down the blood supply to the liver [pringle maneuver], which, however may be associated with severe hepatocellular injury and consequent enhanced morbidity.

20 Apr 2010

Researchers evaluate probiotics' curative effects for treating ulcerative colitis

Inflammatory bowel disease is a chronic recurrent disease, which mainly consists of ulcerative colitis and Crohn's disease, and whose causes are as yet unclear. Many clinical and research studies have indicated that intestinal flora dysbacteriosis contributes to the pathogenesis of ulcerative colitis. Probiotics are non-pathogenic beneficial flora, which have important effects on maintaining the balance of intestinal flora.

20 Apr 2010

Liver Cancer News and Research

Further Reading

Provectus reports on end-of-Phase 2 meeting with FDA on licensure of PV-10 for metastatic melanoma

Study investigates efficacy of acellular dermal matrix for intestinal elongation

OSI Pharmaceuticals announces European Commission's approval of Tarceva for NSCLC

Presence and type of cirrhosis complications are strong predictors of mortality: Study

Investigators study Pioglitazone and Vitamin E for treatment of NASH

SBRT shows promise in treatment of lung, liver and spinal tumors: Clinical experts

ChronSeal multi-center study in Sweden and Norway finalized

FDA grants NexMed clearance for HCC Phase 2 trial for PrevOnco

Pfizer announces discontinuation of SUN 1170 Phase 3 study of Sutent in HCC

New studies on cancer prevention presented at 101st AACR Annual Meeting 2010

COX-2 expression not an adequate independent prognostic factor: Research

Study helps understand molecular mechanism underlying taurine's protection against hepatic fibrosis

Researchers demonstrate role of HSP-90 in portal hypertension

miRNAs may generate new insights on cancer and possible future treatments

Diagnosis of gastric adenomyoma remains a challenging issue

New research indicates patients may develop anemia after gastric bypass surgery

Celsion's ThermoDox Phase I trial data presented at 9th IHPBA World Congress

AngioDynamics commences treatment in NanoKnife IRE System pilot study for HCC

Temporary occlusion of portal vein may help avoid I/R-related complications in liver surgery

Researchers evaluate probiotics' curative effects for treating ulcerative colitis

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News